2. Academic Validation
  3. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period

Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period

  • Auton Neurosci. 2019 May;218:51-53. doi: 10.1016/j.autneu.2019.02.004.
Mark Evans 1,  Mark Butt 2,  Patrice Belanger 3,  Thomas Cummings 4,  Jessica-Lyn Gremminger 4,  Mark Zorbas 1
Affiliations

Affiliations

  • 1 Pfizer Inc., San Diego, CA 92121, United States of America.
  • 2 Tox Path Specialists, LLC, Frederick, MD 21701, United States of America.
  • 3 Pfizer Inc., San Diego, CA 92121, United States of America. Electronic address: Patrice.Belanger@pfizer.com.
  • 4 Pfizer, Inc., Groton, CT 06340, United States of America.
PMID: 30890348 DOI: 10.1016/j.autneu.2019.02.004
Abstract

Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of sympathetic ganglia showed decreased ganglia volume, decreased neuronal size, and increased glial cell density compared with controls after 3 tanezumab treatments. Using stereological techniques to quantify glial cells, the present 26-week study found no significant difference after weekly treatments in total cervicothoracic ganglia satellite glial cell number between placebo- or tanezumab-treated cynomolgus monkeys. These findings suggest that tanezumab treatment does not result in a true gliosis in sympathetic ganglia.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z